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Table 1 Characteristics of SLE pregnancies overall and according to 
aspirin use
Characteristic
All pregnant 
visits 
(n=475)*
Pregnant 
visits with 
aspirin 
(n=121)
Pregnant visits 
without aspirin 
(n=354)
Patient characteristic
Age, mean (SD) 31.0 (4.9) 30.5 (4.6) 31.2 (5.0)
Ethnicity, n (%) 
  Asian 66 (14) 7/66 (11) 59/66 (89)
  Native North American 3 (1) 2/3 (67) 1/3 (33)
  Black 88 (19) 9/88 (10) 79/88 (90)
  Caucasian 209 (44) 71/209 (34) 138/209 (66)
  Hispanic 62 (13) 20/62 (32) 42/62 (68)
  Indian subcontinent 25 (5) 8/25 (32) 17/25 (68)
  Other 22 (5) 4/22 (18) 18/22 (82)
Country, n (%) 
  Canada 121 (25) 27/121 (22) 94/121 (78)
  USA 105 (22) 20/105 (19) 85/105 (81)
  Mexico 52 (11) 19/52 (37) 33/52 (63)
  Europe 146 (31) 49/146 (34) 97/146 (66)
  South Korea 51 (11) 6/51 (12) 45/51 (88)
Any postsecondary education, n (%) 310/452 (69) 69/310 (22) 241/310 (78)
BMI, mean (SD) 25.8 (5.9) 26.3 (5.2) 25.6 (6.1)
Obstetrical history
  Parity, mean (SD) 1.1 (1.0) 1.1 (1.0) 1.2 (1.0)
  Nulliparous, n (%) 134/461 (29) 37/134 (28) 97/134 (72)
  Previous fetal loss <24 weeks, 
n (%)
84/456 (18) 22/84 (26) 62/84 (74)
SLE characteristics
  Disease duration (years), mean (SD) 5.6 (3.3) 5.6 (3.3) 5.6 (3.3)
  SLEDAI, mean (SD) 3.3 (3.8) 3.0 (3.6) 3.4 (3.9)
  SLICC damage score, mean (SD) 0.5 (1.0) 0.6 (1.0) 0.5 (1.0)
  Any positive aPL, n (%) 34/104 (33) 13/34 (38) 21/34 (62)
  LAC, n (%) 19/104 (18) 6/19 (32) 13/19 (68)
  ACL, n (%) 12/104 (12) 3/12 (25) 9/12 (75)
  GP1 IgG, n (%) 18/104 (17) 9/18 (50) 9/18 (50)
  Nephritis, n (%) 53(11) 11/53(21) 42/53 (79)
Comorbidities
  Any renal disease†, n (%) 83 (17) 17/83 (20) 66/83 (80)
  CKD (eGFR≤90 mL/min/1.73 m²), 
n (%)
43/459 (9) 6/43 (14) 37/43 (86)
  CKD stage ≤3 (eGFR≤60 mL/
min/1.73 m²), n (%)
11/459 (2) 5/11 (45) 6/11 (55)
  Hypertension, n (%) 79 (17) 24/79 (30) 55/79 (70)
  Taking anticoagulation, n (%) 28 (6) 12/28 (43) 15/28 (54)
Year of pregnancy visit
  2000– 2004, n (%) 39 (8) 11/39 (28) 28 (72)
  2005– 2009, n (%) 157 (33) 46/157 (29) 111/157 (71)
  2010– 2014, n (%) 218 (46) 52/218 (24) 166/218 (76)
  2015– 2017, n (%) 61 (13) 12/61 (20) 49/61 (80)
*Denominator=475 unless otherwise stated.
†Includes chronic kidney disease, active nephritis and/or nephrotic syndrome within the last 
year.
ACL, anticardiolipin antibody; aPL, antiphospholipid antibody; BMI, body mass index; 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GP1, anti-B2-
glycoprotein-1; LAC, lupus anticoagulant; SLE, systemic lupus erythematosus; SLEDAI, 
Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International 
Collaborating Clinics.
Low aspirin use and high prevalence of pre-
eclampsia risk factors among pregnant women 
in a multinational SLE inception cohort
Women with systemic lupus erythematosus (SLE) carry a 
substantially higher risk for pre-eclampsia compared with the 
general population.1 Aspirin reduces the risk of pre-eclampsia 
in high-risk pregnancies by more than half2 and thus is recom-
mended in SLE.3–5 The European League Against Rheumatism 
recommends aspirin in SLE pregnancies, particularly in those 
with nephritis or positive antiphospholipid antibodies (aPL).5 
Despite this, little is known about current practice. Therefore, 
we assessed the prevalence of aspirin use in SLE pregnancies 
within the Systemic Lupus International Collaborating Clinics 
inception cohort, which has been described elsewhere.6
SLE women aged 18–45 with a pregnancy documented at 
one or more annual study visits (spanning 2000–2017) were 
included. For each pregnant visit, aspirin use, traditional 
pre-eclampsia risk factors (hypertension, chronic kidney 
disease, diabetes, nulliparity, body mass index ≥35, age >40), 
aPL and active lupus nephritis were assessed (see variable defi-
nitions in online supplementary material). Aspirin use was 
compared among those with and without each/any risk factor, 
and over time.
We identified 475 pregnancies among 300 women. Mean 
SLE duration at the time of pregnancy was 5.6 years (SD 3.1). 
Half (51%) of pregnancies had ≥1 traditional pre-eclampsia 
risk factor, 34/104 (33%) had positive aPL and 53/475 (11%) 
had nephritis (table 1). Aspirin was used in 121 (25%) preg-
nancies. While a third of pregnancies in Caucasians (71/209, 
34%, 95% CI 28% to 41%) and Hispanics (20/62, 32%, 95% 
CI 22% to 45%) were aspirin exposed, only 9/88 (10%, 95% 
CI 5% to 18%) and 7/66 (11%, 95% CI 5% to 20%) of preg-
nancies in Black and Asian subjects were respectively aspirin 
exposed. Aspirin use did not differ among pregnancies with or 
without ≥1 traditional risk factor (58/234, 25% (95% CI 20% 
to 31%) vs 63/241, 26% (95% CI 21% to 32%)), any tradi-
tional risk factor individually, or nephritis (see online supple-
mentary table 1). There was a potential trend for increased 
aspirin use among pregnancies with positive aPL (13/34, 38%, 
95% CI 24% to 55%) compared with those without aPL 
(16/70, 23%, 95% CI 15% to 34%), although CI overlapped. 
Sensitivity analyses excluding multiple pregnancies within 
the same women yielded similar results. Aspirin use did not 
increase from 2000 to 2017 (χ2 test for trend in proportions, 
p=0.13).
Our study is the first to assess aspirin use in SLE pregnancies 
according to the presence of pre-eclampsia risk factors. Among 
the 475 SLE pregnancies in this prospective, multinational 
inception cohort, additional pre-eclampsia risk factors were 
present in half, while aspirin was taken in only one-quarter 
and did not differ from background aspirin use among the 
same women at non-pregnant visits (see online supplemen-
tary material). Even without considering SLE itself as a major 
risk factor, aspirin use was no more prevalent among those 
with other traditional indications for aspirin in pregnancy, and 
the majority of those with aPL and nephritis were not taking 
aspirin. The low aspirin use among Black SLE subjects is note-
worthy given the worse reproductive outcomes observed in 
this population.7
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Study limitations include lack of data on gestational age 
and pregnancy outcomes. In addition, aspirin could have been 
introduced at/or following the study visit when the pregnancy 
was documented, highlighting the importance of the rheuma-
tologist in reviewing aspirin use and initiating it, if not already 
done, in pregnant SLE women. However, assuming either a 
somewhat normal or a left-skewed distribution of gestational 
ages at the pregnant visits, a substantial proportion of visits 
would have taken place after 12–16 weeks’ gestation, by which 
time aspirin should have been initiated.2 3
In conclusion, we have potentially identified an important 
gap between practices and current recommendations for the 
care of pregnant SLE women, and call for further studies of 
factors contributing to aspirin use in lupus pregnancies.
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